TABLE 3.
Microarray analysis of chemokinesa
| Gene product | Fold change compared to mock-treated cells
|
|
|---|---|---|
| SARS-CoV | Influenza A virus | |
| Chemokine (C-X-C motif) ligand 11/MIG | 7.9 | 7.7 |
| Chemokine (C-C motif) ligand 8/MCP-2 | 6.5 | 5.5 |
| Chemokine (C-C motif) ligand 20/MIP-3α | 6.5 | 3.9 |
| Chemokine (C-X-C motif) ligand 10/IP-10 | 5.7 | 5.2 |
| Chemokine (C-C motif) ligand 5/RANTES | 3 | 2.1 |
| Chemokine (C-X-C motif) ligand 2/MCP-1 | 1.9 | 2.1 |
| Chemokine (C-C motif) ligand 7/MCP-3 | 1.7 | NC |
| Chemokine (C-C motif) ligand 3/MIP-1α | 1.2 | 2.2 |
Macrophages were infected at an MOI between 1 and 2, and RNAs were extracted at 3 h postinfection. RNAs were pooled from three different donors, and gene expression was analyzed with an Affymetrix U133A Genechip microarray. Many of the chemokine genes were up-regulated in SARS-CoV-infected macrophages and are shown relative to influenza A (H1N1) virus-infected macrophages. A significant up-regulation in gene expression is indicated by an increase of twofold or more and was accompanied by a positive signal intensity call by the Microarray Suite Expression Analysis software, version 5 (Affymetrix Inc.). Only genes that have at least twofold change compared to mock-treated cells are shown. NC, no change compared with mock-treated macrophages.